Overview

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Status:
RECRUITING

Trial end date:
2030-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase II Trial to assess the impact of omitting adjuvant chemotherapy based on patient's selection on treatment persistence of CDK4/6 inhibitor, ribociclib (Kisqali), in a well-defined subgroup of patients with resected estrogen receptor (ER)-positive, HER2-negative, lymph node-positive breast cancer, but whose tumor profiling indicates a less aggressive biological nature (OncotypeDx 21-gene recurrence score RS 0-25).

Phase:

PHASE2

Details

Lead Sponsor:

Yale University

Collaborators:

Breast Cancer Research Foundation
Novartis

Treatments:

Anastrozole
Chemotherapy, Adjuvant
Goserelin
Letrozole
ribociclib